adjustments), as set out in the last financial statements published by Permata prior to the closing of the Transaction. 4. Source of Funds The Bank expects the Transaction to be financed via combination of
Notification of the Capital Market Supervisory Board No. TorChor. 21/2551 re: Rules regarding Connected Transaction and the Notification of the Board of Governor of the Stock Exchange of Thailand re: Disclosure
Price”). The Private Placement Offering Price is at the same price as the Right Offering price, but lower than the Market Price equaling to 20% of the Market Price, and also lower than the fully diluted
Placement Offering Price is at the same price as the Right Offering price, but lower than the Market Price equaling to 20% of the Market Price, and also lower than the fully diluted price (the average share
pursuant to the Notification of the Capital Market Supervisory Board No. TorChor. 20/2551 Re: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets, and the Notification of
นโยบำยกำรลงทุน: กองทุนจะเน้นลงทุนในหน่วยลงทุนของกองทุน Polar Capital Funds plc - Biotechnology ชนิดหน่วยลงทุน I US Dollar (กองทุนหลัก) ซึ่งมีนโยบายลงทุนอย่างน้อย 51% ของ มูลค่าทรัพย์สินในตราสารทุนของบ
per share, in the total sum of Baht 186,300,000. The offering price is not deemed as a price of less than 90% of the market price. The market price is calculated from the weighted average price of the